CLSD Clearside Biomedical Inc.

8.30
+0.15  (2%)
Previous Close 8.15
Open 8.16
Price To book 3.88
Market Cap 210292801
Shares 25,336,482
Volume 93,098
Short Ratio 15.20
Av. Daily Volume 106,515

SEC filingsSee all SEC filings

  1. 8-K - Current report 171046255
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171023172
  3. 8-K - Current report 171016428
  4. 8-K - Current report 171014906
  5. EFFECT - Notice of Effectiveness 17964428

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced July 11, 2017 with three-month preliminary data 1H 2018.
Suprachoroidal CLS-TA - TYBEE
Diabetic Macula Edema (DME)
Phase 1/2 enrollment completion announced April 20, 2017. Preliminary data due 2H 2017.
Suprachoroidal CLS-TA - HULK
Diabetic macular edema (DME)
Announced enrollment of the first patient in its Phase 3 trial - February 16, 2017.
Suprachoroidal CLS-TA - SAPPHIRE
Macular edema associated with retinal vein occlusion (RVO)
Phase 3 completion of enrollment noted August 7, 2017 with preliminary data due 1Q 2018.
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis
Phase 1/2 trial to be initiated following IND submission late 2016.
CLS-1002
Wet age-related macular degeneration (Wet-AMD)

SEC Filings

  1. 8-K - Current report 171046255
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171023172
  3. 8-K - Current report 171016428
  4. 8-K - Current report 171014906
  5. EFFECT - Notice of Effectiveness 17964428
  6. 424B5 - Prospectus [Rule 424(b)(5)] 17963837
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17963811
  8. S-3 - Registration statement under Securities Act of 1933 17943305
  9. 8-K - Current report 17943263
  10. 8-K - Current report 17925223